Table 1.
Outcomes | Group 1 SIRS+ |
Group 2 SIRS+ |
Group 3 SIRS− |
Group 3 SIRS− |
Kruskal–Wallis or Pearson Chi2 | Comparison group | Post hoc p-value |
---|---|---|---|---|---|---|---|
SOFA+ | SOFA− | SOFA+ | SOFA− | ||||
(n = 867) | (n = 153) | (n = 308) | (n = 159) | ||||
ICU mortality, % (n) | 26.8 (233) | 16.3 (25) | 14.2 (44) | 5.6 (9) | Chi2 51.1 | 1 vs. 2 | 0.03 |
p < 0.001 | 1 vs. 3 | <0.001 | |||||
1 vs. 4 | <0.001 | ||||||
2 vs. 3 | 0.44 | ||||||
2 vs. 4 | 0.01 | ||||||
3 vs. 4 | 0.03 | ||||||
Need for MV, % (n) | 68.5 (594) | 45.7 (70) | 54.2 (167) | 20.1 (32) | Chi2 144.8 | 1 vs. 2 | <0.001 |
p < 0.001 | 1 vs. 3 | <0.001 | |||||
1 vs. 4 | <0.001 | ||||||
2 vs. 3 | 0.18 | ||||||
2 vs. 4 | <0.001 | ||||||
3 vs. 4 | <0.001 | ||||||
Length of MV, days, median (IQR) | 6 (3, 13) | 6 (2, 11) | 4 (1, 10) | 2 (1, 7) | Chi2 19.3 | 1 vs. 2 | 0.90 |
p < 0.001 | 1 vs. 3 | 0.004 | |||||
1 vs. 4 | 0.002 | ||||||
2 vs. 3 | 0.22 | ||||||
2 vs. 4 | 0.10 | ||||||
3 vs. 4 | 0.32 | ||||||
Length of ICU stay, days, median (IQR) | 10 (5, 19) | 7 (4, 15) | 7 (4, 15) | 4 (2, 9) | Chi2 83.5 | 1 vs. 2 | <0.001 |
p < 0.001 | 1 vs. 3 | <0.001 | |||||
1 vs. 4 | <0.001 | ||||||
2 vs. 3 | 0.99 | ||||||
2 vs. 4 | <0.001 | ||||||
3 vs. 4 | <0.001 | ||||||
Length of hospitalization, days, median (IQR) | 18 (10, 34) | 14 (8, 29) | 16 (9, 32) | 11 (7, 22) | Chi2 29.9 | 1 vs. 2 | 0.15 |
p < 0.001 | 1 vs. 3 | 0.62 | |||||
1 vs. 4 | <0.001 | ||||||
2 vs. 3 | 0.68 | ||||||
2 vs. 4 | 0.42 | ||||||
3 vs. 4 | <0.001 |
ICU, intensive care unit; IQR, interquartile range; MV, mechanical ventilation; SIRS, systemic inflammatory response syndrome; SOFA, sequential organ failure assessment.
Note: SOFA+, patients with SOFA variation ≥2 over their baseline clinical score. SIRS+, patients with at least 2 of the following signs of SIRS: temperature > 38 °C or <36° C, heart rate > 90 beats per minute, respiratory rate > 20 breaths per minute or PaCO2 < 32 mmHg, abnormal white blood cell count (>12,000/μL or <4000/μL or >10% immature forms).